A mutation in at least one of these genes, previously associated with response to EGFR-targeted antibody therapies, was found in 57.8% of all tumours analysed by pyrosequencing, an increase in K-Ras mutation burden of 27.4% compared with current mandatory analysis of K-Ras mutations restricted to codons 12 and 13, and a 33.3% increase when mutations in B-Raf and PIK3CA were additionally considered. Here, KRAS is linked to neoplasm.